View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 1, 2022

Trialbee to serve as patient recruitment platform for Ergomed’s new centre

The centre will use Trialbee’s RWD-powered recruitment engine and SaaS-based enrolment platform for enrolling subjects.

Trialbee is collaborating with clinical research organisation (CRO) Ergomed to act as the patient recruitment platform for the latter’s newly unveiled Rare Disease Innovation Center.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The collaboration will merge Trialbee Real-World Data (RWD) with Ergomed’s new Site Advantage solution to boost recruitment of patients with rare diseases. 

Furthermore, the partnership will enable improved patient centricity in developing new therapies for rare diseases and bringing them to market rapidly and with reduced costs.

The Site Advantage operating model of Ergomed is tailored to offer support to research sites and patients who are taking part in clinical research for rare diseases. 

The centre will leverage Trialbee’s RWD-powered recruitment engine as well as a SaaS-based enrolment platform for the detection, recruitment and enrolment of subjects.

Furthermore, the Rare Disease Innovation Center, which offers complete trial management services for the largest pharmaceutical firms across the globe, will use Trialbee as its patient identification partner.

Ergomed will leverage the Trialbee Hive solution to enhance referrals and identify patients in an effective manner compared to standard site-based recruitment. 

To boost transparency and inclusivity by tracking referrals at sites, Trialbee Honey will be utilised. 

Trialbee Honey is an end-to-end approach that improves recruitment irrespective of geography or epidemiology.

Trialbee CEO Matt Walz said: “This partnership is about impacting global rare disease research in a meaningful way for our industry.

“By providing a global patient referral ecosystem with Trialbee Hive, triaged through a single onboarding platform with Trialbee Honey and fully enabled by Ergomed Site Advantage, we provide patients a frictionless journey into clinical research for rare disease, while reducing the enrolment on sites.”

In October last year, Trialbee introduced a new centralised software platform designed for recruitment teams to speed up subject recruitment timelines in trials.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena